Investment
Features
FeesSafety
Academy
More
Pluang+

ARK Venture Fund launches tokenized shares on Ethereum, offering exposure to SpaceX, OpenAI, and more.

Protocol Fundamentals
26 Sep 2026
Coinpaper
View Source
Bullish
ARK Venture Fund launches tokenized shares on Ethereum, offering exposure to SpaceX, OpenAI, and more.

ARK and Securitize have introduced a tokenized share class of the ARK Venture Fund, called ARKVX, on the Ethereum blockchain. This allows investors to gain regulated, tokenized exposure to private and public tech companies like SpaceX, OpenAI, and Anthropic through the fund, not by buying direct shares in these companies. The fund remains an actively managed interval fund, meaning liquidity is limited to periodic repurchase offers despite the blockchain-based ownership structure. This move highlights the growing trend of integrating tokenized assets into traditional finance, with ARK envisioning a multi-trillion-dollar market for such assets in the future.

The story about Cathie Wood bringing OpenAI, SpaceX, and Anthropic exposure to Ethereum is presented here with a snapshot of Pluang's cryptocurrency market. For readers following crypto, as of Sep 27, 2026 02:02 WIB, 30 out of 50 major cryptocurrencies rose while 18 fell. Notably, SXP (Solar) dropped sharply by 46.27% to Rp37 with a typical hold time of 94 days, contrasting with FIL (Filecoin) which rose 11.97% to Rp20,600 despite 89% sell orders, and BAL (Balancer) which gained 11.14% to Rp16,297 with a typical hold time of 85 days.

More News

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
3 hours ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
3 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
4 hours ago
Komodo (KMD) token price plunges nearly 50% in one hour amid extremely low trading volume.

Komodo (KMD) token price plunges nearly 50% in one hour amid extremely low trading volume.

The Komodo (KMD) cryptocurrency experienced a sharp price drop of 49.71% within one hour, falling from $0.017987 to $0.009046. This drastic decline occurred despite very low trading activity, with a 24-hour trading volume of less than $1, highlightin...

Market News
Bearish
4 hours ago
XRP price fluctuates between $1.26 and $1.32 amid high on-chain transaction volume

XRP price fluctuates between $1.26 and $1.32 amid high on-chain transaction volume

XRP's price moved between $1.26 and $1.32 within a 24-hour period, closing at $1.30 on Oct. 19. Despite a high on-chain transaction volume exceeding $1.2 billion, this activity does not confirm actual purchases or ownership changes at specific prices...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App